Pulmuone Reports Q1 2026 Consolidated Revenue of 850.3B KRW, Operating Profit of 19.0B KRW, Net Profit Declines

Consolidated Q1 revenue 850.3B KRW, operating profit 19.0B KRW, net profit 5.9B KRW (profitability decline vs annual)
Parent-only Q1 operating revenue 46.9B KRW, operating profit 22.3B KRW, net profit 19.6B KRW (holding company solid)
Consolidated net debt 659.6B KRW, debt ratio 51.8% (slight increase from year-end)
Health care and overseas segments continue losses (healthcare -2.7B, overseas -0.03B)
Hybrid securities improve capital structure but increase interest burden
Partial loss in China JV arbitration (USD 2.2M) poses limited risk
R&D investment of 8.0B KRW (0.9% of sales) maintains technology development
Strong non-financial competitiveness with ESG A+ rating